Focus Advisor Solutions LLC bought a new position in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 24,795 shares of the biopharmaceutical company’s stock, valued at approximately $2,830,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Glenmede Trust Co. NA increased its position in Insmed by 5.4% in the 1st quarter. Glenmede Trust Co. NA now owns 1,916 shares of the biopharmaceutical company’s stock valued at $313,000 after acquiring an additional 98 shares in the last quarter. Waldron Private Wealth LLC lifted its position in shares of Insmed by 1.1% during the third quarter. Waldron Private Wealth LLC now owns 8,910 shares of the biopharmaceutical company’s stock worth $1,017,000 after purchasing an additional 100 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of Insmed by 5.4% during the third quarter. Parallel Advisors LLC now owns 2,275 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 117 shares in the last quarter. Yousif Capital Management LLC grew its stake in shares of Insmed by 4.7% during the third quarter. Yousif Capital Management LLC now owns 2,993 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 134 shares during the last quarter. Finally, SBI Securities Co. Ltd. grew its stake in shares of Insmed by 69.4% during the third quarter. SBI Securities Co. Ltd. now owns 349 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 143 shares during the last quarter.
Analyst Ratings Changes
A number of brokerages recently weighed in on INSM. Weiss Ratings lowered shares of Insmed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. HC Wainwright started coverage on Insmed in a report on Wednesday, November 4th. They set a “buy” rating and a $220.00 price objective on the stock. JPMorgan Chase & Co. decreased their price objective on Insmed from $179.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, August 10th. The Goldman Sachs Group started coverage on Insmed in a research report on Thursday, September 24th. They issued a “buy” rating and a $188.00 price objective on the stock. Finally, Raymond James Financial set a $173.00 target price on Insmed in a research note on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $196.52.
More Insmed News
Here’s some of the latest news about INSM:
- Positive Sentiment: Reports that Sanofi is exploring a potential acquisition drove a strong rally in Insmed shares. One analyst cited in coverage suggested a takeover could value the stock at $170–$210 per share, although no deal has been announced. Insmed shares jump as Sanofi weighs potential takeover
- Neutral Sentiment: An Insmed insider sold 101,100 shares, reducing her stake by about 71%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which may temper concerns that the sale reflects a reaction to recent developments.
- Negative Sentiment: The takeover reports are speculative, and analysts are divided over whether a deal would bring pipeline benefits or create financial strain. The lack of a confirmed offer may contribute to caution and profit-taking after the previous session’s surge. Analysts split on potential Sanofi-Insmed deal
Insmed Price Performance
Shares of INSM stock opened at $141.33 on Friday. Insmed, Inc. has a 52-week low of $90.39 and a 52-week high of $212.75. The stock has a market cap of $31.00 billion, a PE ratio of -50.12 and a beta of 0.83. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.59 and a current ratio of 2.86. The firm’s 50 day moving average price is $111.09 and its two-hundred day moving average price is $122.71.
Insmed (NASDAQ:INSM – Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The business had revenue of $524.43 million for the quarter, compared to the consensus estimate of $500.36 million. Insmed had a negative net margin of 39.85% and a negative return on equity of 96.38%. The business’s revenue was up 268.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.75) EPS. As a group, analysts forecast that Insmed, Inc. will post -1.81 EPS for the current year.
Insider Transactions at Insmed
In other news, insider Orlov S. Nicole Schaeffer sold 101,100 shares of the business’s stock in a transaction dated Thursday, November 19th. The stock was sold at an average price of $145.26, for a total transaction of $14,685,786.00. Following the completion of the transaction, the insider directly owned 41,895 shares in the company, valued at approximately $6,085,667.70. The trade was a 70.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David R. Brennan sold 25,000 shares of the business’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total value of $3,100,000.00. Following the transaction, the director owned 39,238 shares of the company’s stock, valued at $4,865,512. The trade was a 38.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.10% of the company’s stock.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.
Read More
- Five stocks we like better than Insmed
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
